Press Releases

Press Release: Sanofi completes acquisition of Blueprint Medicines

Press Release: Sanofi announces extension of Blueprint tender offer

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Press release: Availability of the Q2 2025 Aide mémoire

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Media Update: EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color

Media Update: ISTH: new data highlight innovation from Sanofi’s pipeline in rare diseases

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs